Lung cancer

CC003

A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer

Trial overview

Topic

CC003

Disease

Lung cancer treatment and diagnosis

Description

Primary Objective:To determine whether the 12-month intracranial relapse rate following HA-PCI is non-inferior compared to the rate following PCI for patients with SCLC. To determine whether HA-PCI reduces the likelihood of 6-month deterioration from baseline in HVLT-R delayed recall compared to the PCI for patients with SCLC.Patient Population:Histologic proof or unequivocal cytologic proof (fine needle aspiration, biopsy or two positive sputa) of SCLC within 250 days prior to Step 1 registration; Zubrod performance status 0-2; Patients who are primary English or French speakers are eligible.

Contact

Michigan

Maria Pappas

Physicians

Thomas Boike

MD

Radiation Oncologist

Clarkston (Radiation oncology) +3

Larry L. Kestin

MD, FACR, FASTRO

Radiation Oncologist

Farmington Hills (Radiation oncology) +2

Alvaro A. Martinez

MD, FACR, FABS, FASTRO

Radiation Oncologist

Pontiac (Radiation oncology) +4

Frank A. Vicini

MD, FACR, FASTRO, FABS

Radiation Oncologist

Farmington Hills (Radiation oncology) +2

John Vito Antonucci

MD

Radiation Oncologist

Madison Heights (Radiation oncology) +3

Michael I. Ghilezan

MD, PhD

Radiation Oncologist

Pontiac (Radiation oncology) +3